The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.
Quiz|Articles|May 15, 2026
OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to sonrotoclax (Beqalzi) for relapsed/refractory mantle cell lymphoma based on results from the phase 1/2 BGB-11417-201 trial (NCT05471843). What overall response rate was reported in patients previously treated with anti-CD20 therapy and a Bruton tyrosine kinase inhibitor?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
3
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
4
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
5